Comparative Study of the Efficacy and Safety of Liposome Encapsulated Botulinum Toxin-A (Lipotoxin) Versus Normal Saline Instillation in Treatment of Patients With Refractory Overactive Bladder Syndrome.

Trial Profile

Comparative Study of the Efficacy and Safety of Liposome Encapsulated Botulinum Toxin-A (Lipotoxin) Versus Normal Saline Instillation in Treatment of Patients With Refractory Overactive Bladder Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 25 Mar 2015 Planned number of patients changed from 80 to 62. ClincalTrials.gov reports enrolment at 62 but treatment only given to eligle patients n=24.
    • 21 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Aug 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top